Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Blaney

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Pediatric Blood & Cancer|April 26, 2018
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology GroupMeredith K Chuk, Brigitte C Widemann, Charles G Minard, et al.
Pediatric Blood & Cancer|December 10, 2008
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumorsMark W Kieran, Jeffrey G Supko, Dana Wallace, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Testing of new agents in childhood cancer preclinical models: meeting summaryPeter J Houghton, Peter C Adamson, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2024
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS TumorsFrank Y Lin, Austin Stuckert, Candise Tat, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Pediatric Blood & Cancer|April 26, 2018
A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology GroupMeredith K Chuk, Brigitte C Widemann, Charles G Minard, et al.
Pediatric Blood & Cancer|December 10, 2008
Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumorsMark W Kieran, Jeffrey G Supko, Dana Wallace, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2002
Testing of new agents in childhood cancer preclinical models: meeting summaryPeter J Houghton, Peter C Adamson, Susan Blaney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2024
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS TumorsFrank Y Lin, Austin Stuckert, Candise Tat, et al.
Pageof 3